Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing
Mandate

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

February 15, 2016

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Related

Vinge advises Smart Eye on acquisition of Sightic Analytics

 Smart Eye has entered into an agreement to acquire all shares in Sightic Analytics for a fixed purchase price of SEK 60.5 million, to be paid with newly issued shares in Smart Eye, and an additional purchase price of up to SEK 50 million, conditional upon certain financial and operational targets being met.
February 24, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Baker Tilly Uppsala AB and Baker Tilly Guide AB.
February 22, 2026

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

 Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026